» Articles » PMID: 27791120

Structural Flexibility at a Major Conserved Antibody Target on Hepatitis C Virus E2 Antigen

Overview
Specialty Science
Date 2016 Oct 30
PMID 27791120
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) is a major cause of liver disease, affecting over 2% of the world's population. The HCV envelope glycoproteins E1 and E2 mediate viral entry, with E2 being the main target of neutralizing antibody responses. Structural investigations of E2 have produced templates for vaccine design, including the conserved CD81 receptor-binding site (CD81bs) that is a key target of broadly neutralizing antibodies (bNAbs). Unfortunately, immunization with recombinant E2 and E1E2 rarely elicits sufficient levels of bNAbs for protection. To understand the challenges for eliciting bNAb responses against the CD81bs, we investigated the E2 CD81bs by electron microscopy (EM), hydrogen-deuterium exchange (HDX), molecular dynamics (MD), and calorimetry. By EM, we observed that HCV1, a bNAb recognizing the N-terminal region of the CD81bs, bound a soluble E2 core construct from multiple angles of approach, suggesting components of the CD81bs are flexible. HDX of multiple E2 constructs consistently indicated the entire CD81bs was flexible relative to the rest of the E2 protein, which was further confirmed by MD simulations. However, E2 has a high melting temperature of 84.8 °C, which is more akin to proteins from thermophilic organisms. Thus, recombinant E2 is a highly stable protein overall, but with an exceptionally flexible CD81bs. Such flexibility may promote induction of nonneutralizing antibodies over bNAbs to E2 CD81bs, underscoring the necessity of rigidifying this antigenic region as a target for rational vaccine design.

Citing Articles

Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodies.

Nagarathinam K, Scheck A, Labuhn M, Stroh L, Herold E, Veselkova B Sci Adv. 2024; 10(49):eado2600.

PMID: 39642219 PMC: 11623273. DOI: 10.1126/sciadv.ado2600.


Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study.

Sepulveda-Crespo D, Volpi C, Amigot-Sanchez R, Yelamos M, Diez C, Gomez J Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338314 PMC: 11434851. DOI: 10.3390/ph17091152.


The hepatitis C virus envelope protein complex is a dimer of heterodimers.

Augestad E, Olesen C, Gronberg C, Soerensen A, Velazquez-Moctezuma R, Fanalista M Nature. 2024; 633(8030):704-709.

PMID: 39232163 DOI: 10.1038/s41586-024-07783-5.


Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.

Pierce B, Felbinger N, Metcalf M, Toth E, Ofek G, Fuerst T Viruses. 2024; 16(5).

PMID: 38793684 PMC: 11125608. DOI: 10.3390/v16050803.


HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies.

Zhang H, Bull R, Quadeer A, McKay M Virus Evol. 2023; 9(2):vead068.

PMID: 38107333 PMC: 10722114. DOI: 10.1093/ve/vead068.


References
1.
Tokuriki N, Oldfield C, Uversky V, Berezovsky I, Tawfik D . Do viral proteins possess unique biophysical features?. Trends Biochem Sci. 2008; 34(2):53-9. DOI: 10.1016/j.tibs.2008.10.009. View

2.
Ludtke S, Baldwin P, Chiu W . EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999; 128(1):82-97. DOI: 10.1006/jsbi.1999.4174. View

3.
Sanders R, Derking R, Cupo A, Julien J, Yasmeen A, de Val N . A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013; 9(9):e1003618. PMC: 3777863. DOI: 10.1371/journal.ppat.1003618. View

4.
Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W . Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PLoS One. 2013; 8(12):e82598. PMC: 3866230. DOI: 10.1371/journal.pone.0082598. View

5.
Pawlotsky J, Feld J, Zeuzem S, Hoofnagle J . From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62(1 Suppl):S87-99. DOI: 10.1016/j.jhep.2015.02.006. View